Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2013

View Archived Issues

Dual M3 receptor/beta2-adrenoceptor antagonists/agonists disclosed by Chiesi Farmaceutici

Research alliance expands miRNA targets

Encouraging phase IIb results for Nexagon in chronic venous leg ulcers

Inovio Pharmaceuticals prepares for clinical trial of HCV vaccine

Galapagos receives grant from Flemish government to support antibacterial research

Adimab expands collaborations with Merck & Co. and Lilly

BIND Biosciences and Amgen to develop a kinase inhibitor nanomedicine

Cell Therapeutics begins enrollment in phase III PERSIST-1 trial

FDA grants fast track designation to enobosarm for muscle wasting in NSCLC

Novel 11-beta-HSD1 inhibitor with potential for treating diabetes identified at Pfizer

Experiments with FH-535 implicate Wnt signaling pathway in triple-negative breast cancer

CHAMPION PHOENIX phase III trial meets primary endpoint

Altravax receives NIH grants for additional testing of vaccine candidates

Chinese researchers patent new coumarin derivatives

OPKO Health to expand pipeline with acquisition of Cytochroma

ALS Therapy Development Institute and to-BBB sign collaboration agreement

FDA accepts resubmission of NDA for sugammadex sodium injection

Eli Lilly discloses novel metabotropic glutamate receptor agonists

Novel prodrugs of vilazodone presented by Nectid

Combining gamma-secretase inhibitors with endocrine therapy shows promise in relapsed MBC

SK Biopharmaceuticals divulges new 1-beta-HSD1 inhibitors

NewVac and Janssen sign license and development agreement

Pierre Fabre Medicament synthesizes novel alpha-adrenoceptor antagonists

Oramed submits IND application for phase II trial of oral insulin candidate

FDA advisory committee recommends approval of canagliflozin

Phase I data reported for breast cancer treatment MM-302

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...